ABCG2 and cancer: Nanocarriers have effectively overcome challenges of limited aqueous solubility, low bioavailability, lack of targeting cancer tissues, increase drug therapeutic index, preferential accumulation by EPR effect and divert ABC-transporter mediated drug efflux MDR with potential to be multi-functionalized for cancer treatment.